This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2020
Kate
Conference Operator
Good afternoon. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the CarioPharm Therapeutics 3rd Quarter 2020 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that the call is being recorded by the company's request. I would now like to turn the call over to Mr. Ian Karp, CarioPharm Therapeutics Senior Vice President, Investor of Public Relations.
Ian Karp
Senior Vice President, Investor & Public Relations
Thank you, Kate, and thank you all for joining us on today's conference call to discuss CarioPharm's third quarter 2020 financial results and business update. This is Ian Karp, and I'm joined today by Dr. Michael Kaufman, Chief Executive Officer, Dr. Sharon Shacham, President and Chief Scientific Officer, Mr. Mike Mason, Chief Financial Officer, Mr. John Demery, Chief Commercial Officer, Mr. Christopher Permiano, Chief Business Officer and General Counsel, and Dr. Jayton Shaw, Chief Medical Officer. On the call today, Michael and John will provide an overview of key recent corporate developments and an update on our commercial progress, and then Mike Mason will provide an overview of the third quarter 2020 financial results.
Ian Karp
Senior Vice President, Investor & Public Relations
We will conclude with the Q&A portion of our call.
You're reading a preview of the KPTI Q3 2020 earnings call.
Free account.
Disclaimer